19-38906009-C-T
Variant names:
Variant summary
Our verdict is Benign. The variant received -12 ACMG points: 0P and 12B. BP4_StrongBA1
The NM_002503.5(NFKBIB):c.619+474C>T variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.213 in 151,974 control chromosomes in the GnomAD database, including 3,695 homozygotes. In-silico tool predicts a benign outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.
Frequency
Genomes: 𝑓 0.21 ( 3695 hom., cov: 31)
Consequence
NFKBIB
NM_002503.5 intron
NM_002503.5 intron
Scores
2
Clinical Significance
Not reported in ClinVar
Conservation
PhyloP100: -0.829
Publications
14 publications found
Genes affected
NFKBIB (HGNC:7798): (NFKB inhibitor beta) The protein encoded by this gene belongs to the NF-kappa-B inhibitor family, which inhibit NF-kappa-B by complexing with, and trapping it in the cytoplasm. Phosphorylation of serine residues on these proteins by kinases marks them for destruction via the ubiquitination pathway, thereby allowing activation of the NF-kappa-B, which translocates to the nucleus to function as a transcription factor. Alternatively spliced transcript variants have been found for this gene.[provided by RefSeq, Jul 2011]
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -12 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.87).
BA1
GnomAd4 highest subpopulation (EAS) allele frequency at 95% confidence interval = 0.355 is higher than 0.05.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| NFKBIB | NM_002503.5 | c.619+474C>T | intron_variant | Intron 3 of 5 | ENST00000313582.6 | NP_002494.2 |
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| NFKBIB | ENST00000313582.6 | c.619+474C>T | intron_variant | Intron 3 of 5 | 1 | NM_002503.5 | ENSP00000312988.5 |
Frequencies
GnomAD3 genomes AF: 0.214 AC: 32434AN: 151856Hom.: 3697 Cov.: 31 show subpopulations
GnomAD3 genomes
AF:
AC:
32434
AN:
151856
Hom.:
Cov.:
31
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
We have no GnomAD4 exomes data on this position. Probably position not covered by the project.
GnomAD4 genome AF: 0.213 AC: 32431AN: 151974Hom.: 3695 Cov.: 31 AF XY: 0.216 AC XY: 16046AN XY: 74288 show subpopulations
GnomAD4 genome
AF:
AC:
32431
AN:
151974
Hom.:
Cov.:
31
AF XY:
AC XY:
16046
AN XY:
74288
show subpopulations
African (AFR)
AF:
AC:
6358
AN:
41428
American (AMR)
AF:
AC:
2898
AN:
15270
Ashkenazi Jewish (ASJ)
AF:
AC:
866
AN:
3470
East Asian (EAS)
AF:
AC:
1903
AN:
5164
South Asian (SAS)
AF:
AC:
1191
AN:
4824
European-Finnish (FIN)
AF:
AC:
2644
AN:
10540
Middle Eastern (MID)
AF:
AC:
77
AN:
294
European-Non Finnish (NFE)
AF:
AC:
15799
AN:
67964
Other (OTH)
AF:
AC:
459
AN:
2108
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.503
Heterozygous variant carriers
0
1246
2492
3738
4984
6230
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Age Distribution
Genome Het
Genome Hom
Variant carriers
0
356
712
1068
1424
1780
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
867
AN:
3478
ClinVar
Not reported inComputational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
DANN
Benign
PhyloP100
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.